We are led by experienced biopharma executives with exceptional track records of building strong companies, delivering innovative treatments and growing diverse teams.
We are building a portfolio of pre-clinical to late-stage assets with the potential to become the next great innovation in immunology, providing clinically meaningful treatments to patients.
We are guided by our values of courage, compassion, collaboration, innovation and a sense of urgency. We care as people, and we care as scientists.
We have the right blend of experience, along with a broad network of contacts, needed to advance programs that can dramatically transform patients’ lives.
We are building a different kind of biopharma company focused on developing and delivering therapeutics through efficient and ongoing collaboration.
ACELYRIN can access promising therapeutic programs through our global network of relationships across pharma and biotech, finance and academia.
We conduct a licensing and acquisition search process that is both directed and opportunistically focused on platforms, programs and products when compelling science or data exist.
We are actively investigating the potential of izokibep and other programs in diseases where differentiated therapeutic approaches are required to address unmet patient needs.
Partnering with ACELYRIN
Partnering with ACELYRIN
Maximizing Shareholder Value
For Investors
